Sanofi announces the publication by the NEJM (New England Journal of Medicine) of Phase III data on its investigational once-weekly drug efanesoctocog alpha, which 'illustrate its potential to transform the treatment of hemophilia A'.

These data demonstrate that efanesoctocog alpha achieves normal or near-normal levels of factor VIII activity (greater than 40%) for the majority of the week on a once-weekly dose", says the healthcare group.

Sanofi points out that its efanesoctocog alpha is currently under accelerated review by the U.S. Food and Drug Administration (FDA), with a decision expected on February 28.

Copyright (c) 2023 CercleFinance.com. All rights reserved.